Tag:

Hospira

Latest Headlines

Latest Headlines

Hospira's Remicade biosimilar wins large French contract with deep discount

Hospira continues to forge a new market reality around biosimilars, capturing wide swathes of market share with deep discounts for its biosimilar of Merck's arthritis blockbuster Remicade. Hospira has reportedly captured a public contract in France by offering a price that amounts to a 45% savings.

UPDATED: Hospira finally up and running at its cost-cutting India plant

After dealing with two preapproval inspections and two dozen FDA observations, injectables specialist Hospira says it has gotten FDA approval and is ramping up production at its new plant in India.

UPDATED: Hospira gets FDA OK for massive India plant from which Pfizer will reap the rewards

The game is on at Hospira's massive new manufacturing plant in India. After two delays to work out kinks identified by the FDA, the drugmaker says the agency has signed off on it and Hospira has started "limited commercial production at the facility."

Health Canada bans Hospira drugs coming from Italy plant

Two months ago, the FDA issued a warning letter for a Hospira plant in Italy noting a number of problems including its lack of controls for access to prevent data deletions from test equipment. Health Canada has decided that issue is enough for it to ban products coming out of the sterile manufacturing facility.

Hospira execs called 'shameful' for denying cybersecurity risks posed by their infusion pumps

It's been more than a year since cybersecurity guru Billy Rios flagged Hospira's PCA 3 Lifecare infusion pumps for its poor cybersecurity. The issues have gone unaddressed, Rios says in a critical blog post, writing "we have yet to see a single fix for the issues affecting the PCA 3."

Samsung Bioepis, Celltrion propel South Korea to front ranks of biosimilar race

South Korea's Celltrion and Samsung Bioepis are poised to gain new or expanded approval for biosimilars of some of the world's best-selling biological drugs, setting up a regulatory knowledge base on approvals and bringing commercial competition to major drugmakers not unlike that seen by small-molecule generics from India decades ago.

Inflectra vs. Remicade study could be just what the doctor ordered for biosimilars

A study released today that pitted Hospira's biosimilar Inflectra against its reference drug Remicade in patients with rheumatoid arthritis is good news for Hospira, and by default Pfizer. It found that patients who were switched to the copy did just as well, with no unexpected side effects, as they had on Merck and Johnson & Johnson's Remicade.

Hospira again shipping ketorolac but U.S. faces many drug shortages

Hospira recalled more than 60 lots of the pain reliever ketorolac tromethamine injection in January because of the potential for crystals in the 18 million vials that had been shipped in the U.S. and Singapore.

Hospira recalls solution marked as heparin

Hospira is voluntarily recalling 181,704 bags of magnesium sulfate in 5% dextrose injections because labels on the immediate container may have barcodes indicating that it is instead the blood thinner heparin.

Homeland Security: Hospira infusion pump vulnerable to cyberattack from low-skilled hacker

The Department of Homeland Security warned that due to a cybersecurity flaw, a low-skilled remote hacker could alter the configurations of Hospira's LifeCare PCA Infusion System.